Hair Loss Disorders (Alopecias)

    May 2025 in “ Medicine ”
    Elisabetta Muttoni, Susan Holmes
    Studysummary This article discusses hair loss disorders, underscoring the recent therapeutic advance of ritlecitinib, approved for severe alopecia areata in individuals aged 12 and older, and the ongoing need to manage expectations given limited treatment options.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on medicinejournal.co.uk →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Treatment Options for Androgenetic Alopecia: Efficacy, Side Effects, Compliance, Financial Considerations, and Ethics Journal of Cosmetic Dermatology · 2021
    2. Trichodynia and Telogen Effluvium in COVID-19 Patients: Results of an International Expert Opinion Survey on Diagnosis and Management JAAD International · 2021